Key Points
-
'Membranoproliferative' is a descriptive term for a morphological pattern of glomerular injury characterized by an enlarged mesangium and capillary wall thickening with double contours
-
Membranoproliferative changes are usually caused by deposition of immunoglobulin and/or complement in glomeruli, in which case the disease is called membranoproliferative glomerulonephritis (MPGN)
-
Many cases of MPGN are caused by defective control of the alternative complement pathway, associated with dominant C3 deposition in glomeruli with little immunoglobulin, and are now classified as C3 glomerulopathies
-
C3 glomerulopathies can be divided into dense deposit disease and C3 glomerulonephritis, depending on the ultrastructural appearance by electron microscopy
-
Recognition of the underlying cause of MPGN is important to guide investigation and treatment
Abstract
'Membranoproliferative' describes glomerular injury characterized by capillary wall thickening and mesangial expansion owing to increased matrix deposition and hypercellularity. The presence of immune deposits is indicative of membranoproliferative glomerulonephritis (MPGN). Historically, MPGN was further classified into three types according to the appearance and site of the electron-dense deposits seen by electron microscopy, but it is now recognized that many cases show only deposition of the complement component C3, owing to abnormal control of the alternative pathway of complement activation—these cases are now classified as C3 glomerulopathies. Not all cases of C3 glomerulopathy, however, show an MPGN pattern. C3 glomerulopathies include dense deposit disease, which shows dense osmiophilic deposits, and C3 glomerulonephritis, which shows isolated deposits. In many cases, the genetic mutations or autoantibodies responsible for C3 deposition have been identified. Some patients in whom complement control is abnormal will accumulate small amounts of immunoglobulin in their glomeruli and so, in everyday practice, the morphological diagnosis of 'glomerulonephritis with dominant C3' is useful for identifying patients who require investigation of the complement pathway. The recognition that many cases of MPGN are C3 glomerulopathies and that the underlying cause can often be identified in immunoglobulin-associated cases means that the diagnosis of idiopathic MPGN is now very uncommon.
Similar content being viewed by others
References
Taal, M. W. et al. (eds.) Brenner and Rector's The Kidney (Elsevier, 2012).
Fakhouri, F. et al. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 6, 494–499 (2010).
Churg, J., Bernstein, J. & Glassock R. J. Renal Disease: Classification and Atlas of Glomerular Diseases 2nd edn (Igaku-Shoin, 1995).
Jones, D. B. Glomerulonephritis. Am. J. Pathol. 29, 33–51 (1953).
Porter, K. A. et al. Human renal transplants. I. Glomerular changes. Lab. Invest. 16, 153–181 (1967).
Husain, S. & Sis, B. Advances in the understanding of transplant glomerulopathy. Am. J. Kidney Dis. 62, 352–363 (2013).
Levy, M. et al. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin. Immunol. Immunopathol. 10, 477–492 (1978).
Berger, J. & Galle, P. Depots dense au sein des membranes basales du rein: etude en microscopies optique et electronique [French]. Presse Med. 71, 2351–2354 (1963).
Habib, R. et al. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int. 7, 204–215 (1975).
Appel, G. B. et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J. Am. Soc. Nephrol. 16, 1392–1403 (2005).
Smith, R. J. et al. New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 18, 2447–2456 (2007).
Burkholder, P. M., Marchand, A. & Krueger, R. P. Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study. Lab. Invest. 23, 459–479 (1970).
Strife, C. F., McEnery, P. T., McAdams, A. J. & West, C. D. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin. Nephrol. 7, 65–72 (1977).
Anders, D., Agricola, B., Sippel, M. & Thoenes, W. Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections. Virchows Arch. A. Pathol. Anat. Histol. 376, 1–19 (1977).
Sethi, S. & Fervenza, F. C. Membranoproliferative glomerulonephritis—a new look at an old entity. N. Engl. J. Med. 366, 1119–1131 (2012).
Sethi, S. & Fervenza, F. C. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin. Nephrol. 31, 341–348 (2011).
Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241–250 (2004).
Alpers, C. E. & Smith, K. D. Cryoglobulinemia and renal disease. Curr. Opin. Nephrol. Hypertens. 17, 243–249 (2008).
Kawamura, T. et al. Primary membranoproliferative glomerulonephritis on the decline: decreased rate from the 1970s to the 2000s in Japan. Clin. Exp. Nephrol. 17, 248–254 (2013).
Johnson, R. J. et al. Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide. Am. J. Kidney Dis. 42, 575–581 (2003).
Nasr, S. H. et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J. Am. Soc. Nephrol. 20, 2055–2064 (2009).
Nasr, S. H. et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin. J. Am. Soc. Nephrol. 6, 775–784 (2011).
Rosenstock, J. L. et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int. 63, 1450–1461 (2003).
Fervenza, F. C., Sethi, S. & Glassock, R. J. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol. Dial. Transplant. 27, 4288–4294 (2012).
Habib, R. et al. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int. 7, 204–215 (1975).
Jenis, E. H. et al. Glomerulonephritis with basement membrane dense deposits. Arch. Pathol. 97, 84–91 (1974).
Pickering, M. C. et al. C3 glomerulopathy: consensus report. Kidney Int. 84, 1079–1089 (2013).
Nasr, S. H. et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 4, 22–32 (2009).
Walker, P. D., Ferrario, F., Joh, K. & Bonsib S. M. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod. Pathol. 20, 605–616 (2007).
Herlitz, L. C. et al. Pathology after eculizumab in dense deposit disease and C3 GN. J. Am. Soc. Nephrol. 23, 1229–1237 (2012).
Servais, A. et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82, 454–464 (2012).
Medjeral-Thomas, N. R. et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin. J. Am. Soc. Nephrol. 9, 46–53 (2014).
Hou, J. et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 85, 450–456 (2014).
West, C. D. Nephritic factors predispose to chronic glomerulonephritis. Am. J. Kidney Dis. 24, 956–963 (1994).
Vallota, E. H. et al. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J. Exp. Med. 139, 1249–1261 (1974).
Schwertz, R. et al. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr. Allergy Immunol. 12, 166–172 (2001).
Lu, D. F. et al. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr. Nephrol. 27, 773–781 (2012).
Cameron, J. S. et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am. J. Med. 74, 175–192 (1983).
Bennett, W. M. et al. Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease. Am. J. Kidney Dis. 13, 469–476 (1989).
Little, M. A. et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 69, 504–511 (2006).
Pickering, M. C. & Cook, H. T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin. Exp. Immunol. 151, 210–230 (2008).
Licht, C. et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 70, 42–50 (2006).
Jokiranta, T. S. et al. Nephritogenic λ light chain dimer: a unique human miniautoantibody against complement factor H. J. Immunol. 163, 4590–4596 (1999).
Martinez-Barricarte, R. et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 120, 3702–3712 (2010).
Athanasiou, Y. et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin. J. Am. Soc. Nephrol. 6, 1436–1446 (2011).
Deltas, C. et al. C3 glomerulonephritis/CFHR5 nephropathy is an endemic disease in Cyprus: clinical and molecular findings in 21 families. Adv. Exp. Med. Biol. 734, 189–196 (2013).
Vernon, K. A. et al. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am. J. Transplant. 11, 152–155 (2011).
Tortajada, A. et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J. Clin. Invest. 123, 2434–2446 (2013).
Gale, D. P. et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376, 794–801 (2010).
Medjeral-Thomas, N. et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int. 85, 933–937 (2014).
Neary, J. et al. Familial membranoproliferative glomerulonephritis type III. Am. J. Kidney Dis. 40, E1 (2002).
Malik, T. H. et al. A hybrid CFHR3–1 gene causes familial C3 glomerulopathy. J. Am. Soc. Nephrol. 23, 1155–1160 (2012).
Neary, J. J. et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J. Am. Soc. Nephrol. 13, 2052–2057 (2002).
Zhang, Y. et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin. J. Am. Soc. Nephrol. 7, 265–274 (2012).
Abrera-Abeleda, M. A. et al. Allelic variants of complement genes associated with dense deposit disease. J. Am. Soc. Nephrol. 22, 1551–1559 (2011).
Sethi, S. et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int. 83, 293–299 (2013).
Sandhu, G. et al. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am. J. Kidney Dis. 60, 1039–1043 (2012).
Little, M. A., Dupont, P., Campbell, E., Dorman, A. & Walshe, J. J. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 69, 504–511 (2006).
Braun, M. C. et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J. Am. Soc. Nephrol. 16, 2225–2233 (2005).
Zand, L. et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J. Am. Soc. Nephrol. 25, 1110–1117 (2014).
Acknowledgements
The authors' research is supported by the NIHR Imperial Biomedical Research Centre and grants from the Wellcome Trust and Kidney Research UK. M.C.P. is a Wellcome Trust Senior Fellow in Clinical Science (WT098476MA).
Author information
Authors and Affiliations
Contributions
Both authors contributed to researching data for the article, discussion of its content, writing the article, and review and editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Cook, H., Pickering, M. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 11, 14–22 (2015). https://doi.org/10.1038/nrneph.2014.217
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.217
- Springer Nature Limited
This article is cited by
-
WT1 complete gonadal dysgenesis with membranoproliferative glomerulonephritis: case series and literature review
Pediatric Nephrology (2022)
-
Gross hematuria, edema, and hypocomplementemia in a 9-year-old boy: Answers
Pediatric Nephrology (2022)
-
C3 glomerulopathy and atypical hemolytic uremic syndrome: an updated review of the literature on alternative complement pathway disorders
International Urology and Nephrology (2021)
-
Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature
BMC Nephrology (2020)
-
The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis
BMC Nephrology (2020)